EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 Janeiro 2024 - 9:00AM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed
to developing and commercializing therapeutics to improve the lives
of patients with serious retinal diseases, today announced that the
Company granted non-statutory stock options to a new employee as an
inducement award outside the Company’s 2023 Long-Term Incentive
Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up
to 10,000 shares of EyePoint Pharmaceuticals common stock to one
new employee. The stock options were granted on January 12, 2023.
The grant was approved by the Compensation Committee and made as an
inducement material to the employee entering into employment with
EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule
5635(c)(4). The option award has an exercise price of $22.76 per
share, the closing price of EyePoint Pharmaceuticals’ common stock
on January 12, 2024. The options have a ten-year term and vest over
four years, with 25% of the original number of shares vesting on
the first anniversary of the applicable employee’s date of grant
and the remainder vesting in equal monthly installments over the
following three years. Vesting of the options is subject to the
employee’s continued service with EyePoint Pharmaceuticals through
the applicable vesting dates.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
clinical-stage biopharmaceutical company committed to developing
and commercializing therapeutics to help improve the lives of
patients with serious retinal diseases. The Company's pipeline
leverages its proprietary bioerodible Durasert E™ technology for
sustained intraocular drug delivery. The Company’s lead product
candidate, EYP-1901, is an investigational sustained delivery
treatment for VEGF-mediated retinal diseases combining vorolanib, a
selective and patent-protected tyrosine kinase inhibitor with
Durasert E™. Additional pipeline programs include EYP-2301, a
promising TIE-2 agonist, razuprotafib, f/k/a AKB-9778, formulated
in Durasert E™ to potentially improve outcomes in serious retinal
diseases. The proven Durasert® drug delivery technology has been
safely administered to thousands of patient eyes across four U.S.
FDA approved products. EyePoint Pharmaceuticals is headquartered in
Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by
Equinox Sciences for the localized treatment of all ophthalmic
diseases outside of China, Macao, Hong Kong and Taiwan.
For EyePoint Pharmaceuticals:
Investors:Christina TartagliaStern
IRDirect: 212-698-8700christina.tartaglia@sternir.com
Media Contact:Amy PhillipsGreen
Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024